Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead (“Purchaser”...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of the tender offer by its wholly-owned subsidiary, Dodgers Merger Sub, Inc. (“Purchaser”), for all of the...
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE PR Newswire NEW YORK, Aug. 31, 2017 NEW YORK, Aug. 31, 2017 /PRNewswire/ -- Juan...
Harwood Feffer LLP Announces Investigation of Kite Pharma, Inc. PR Newswire NEW YORK, Aug. 29, 2017 NEW YORK, Aug. 29, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating...
Rowley Law PLLC is investigating potential claims against Kite Pharma, Inc. (NASDAQ: KITE) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of...
-- Immediately Positions Gilead as a Leader in Cell Therapy -- -- Kite’s Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in...
Study Demonstrates the Potential of TCR Engineered T-Cell Therapy to Induce Remissions in Solid Tumors KITE-718, Utilizing Same TCR Construct and Next-Generation T-Cell Manufacturing...
Filed Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel for Potential EU Approval and Launch in 2018 Submitted Investigational New Drug...
Internally Generated Cell Therapy Candidate Engineered with Fully Human Anti-BCMA Construct Next-Generation Manufacturing Process Designed for Enhanced Product Potency and Activity...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
